Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
- 1 October 1999
- journal article
- Published by Elsevier BV in Journal of Molecular Biology
- Vol. 293 (1), 41-56
- https://doi.org/10.1006/jmbi.1999.3156
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1998
- The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodiesFEBS Letters, 1998
- Remodeling domain interfaces to enhance heterodimer formationProtein Science, 1997
- Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20Published by Elsevier BV ,1996
- High Level Secretion of a Humanized Bispecific Diabody from Escherichia coliNature Biotechnology, 1996
- Crystal structure of a diabody, a bivalent antibody fragmentStructure, 1994
- Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: Production of bivalent and biotinylated miniantibodiesMolecular Immunology, 1994
- A novel strategy for production of a highly expressed recombinant protein in an active formFEBS Letters, 1991
- Cloning and sequencing of the gene for the DNA-binding 17 K protein of Escherichia coliGene, 1988
- Gene regulation at the right operator (OR) of bacteriophage λJournal of Molecular Biology, 1980